Patient Outcomes Following SBRT Versus IR-based Procedures for Early Stage NSCLC

Abstract

RPA identified age 78 years, Charlson score 5, %DLCO < 71%, % FEV1 < 65%, tumor size 3 cm and SUV max 12 as significant cutoffs for adverse PFS outcome. RPA identified %DLCO < 71%, tumor size 3 cm and SUV max 12 as significant cutoffs for adverse TTP. On multivariate analysis, age (pZ0.05), Charlson score (pZ0.03), %DLCO (pZ0.00001), non-adenocarcinoma histology (pZ0.02), and tumor size (pZ0.002) remained predictive of PFS. Correlations with biological markers are currently ongoing. Conclusion: Age 78 years, Charlson score 5, %DLCO < 71%, tumor size 3 cm and non-adenocarcinoma histology were found to be independent predictors of PFS. Patients with %DLCO < 71%, tumor size 3 cm and SUV max 12 had adverse TTP outcomes, suggesting that they may benefit from treatment intensification. A predictive model is being develop and will be presented.